Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary breast cancer (DCIS or invasive), and some ultimately die of breast cancer. OBJECTIVE: To estimate the 10- and 20-year mortality from breast cancer following a diagnosis of DCIS and to establish whether the mortality rate is influenced by age at diagnosis, ethnicity, and initial treatment received. DESIGN, SETTING, AND PARTICIPANTS: Observational study of women who received a diagnosis of DCIS from 1988 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Age at diagnosis, race/ethnicity, pathologic features, date of second primary breast cancer, cause of death, and survival were abstracted for 108,196 women. Their risk of dying of breast cancer was compared with that of women in the general population. Cox proportional hazards analysis was performed to estimate the hazard ratio (HR) for death from DCIS by age at diagnosis, clinical features, ethnicity, and treatment. MAIN OUTCOMES AND MEASURES: Ten- and 20-year breast cancer-specific mortality. RESULTS: Among the 108 196 women with DCIS, the mean (range) age at diagnosis of DCIS was 53.8 (15-69) years and the mean (range) duration of follow-up was 7.5 (0-23.9) years. At 20 years, the breast cancer-specific mortality was 3.3% (95% CI, 3.0%-3.6%) overall and was higher for women who received a diagnosis before age 35 years compared with older women (7.8% vs 3.2%; HR, 2.58 [95% CI, 1.85-3.60]; P < .001) and for blacks compared with non-Hispanic whites (7.0% vs 3.0%; HR, 2.55 [95% CI, 2.17-3.01]; P < .001). The risk of dying of breast cancer increased after experience of an ipsilateral invasive breast cancer (HR, 18.1 [95% CI, 14.0-23.6]; P < .001). A total of 517 patients died of breast cancer following a DCIS diagnosis (mean follow-up, 7.5 [range, 0-23.9] years) without experiencing an in-breast invasive cancer prior to death. Among patients who received lumpectomy, radiotherapy was associated with a reduction in the risk of ipsilateral invasive recurrence at 10 years (2.5% vs 4.9%; adjusted HR, 0.47 [95% CI, 0.42-0.53]; P < .001) but not of breast cancer-specific mortality at 10 years (0.8% vs 0.9%; HR, 0.86 [95% CI, 0.67-1.10]; P = .22). CONCLUSIONS AND RELEVANCE: Important risk factors for death from breast cancer following a DCIS diagnosis include age at diagnosis and black ethnicity. The risk of death increases after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences by radiotherapy does not diminish breast cancer mortality at 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) (2014) · The Lancet · doi:10.1016/s0140-6736(14)60488-8 · Cited by 2,254
WHO classification of tumours of the breast
Lakhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P. H., & van de Vijver, M. J. (2012) · International Agency for Research on Cancer eBooks · Cited by 1,524
Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., Land, S. R., Margolese, R. G., Swain, S. M., Costantino, J. P., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr027 · Cited by 785
The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast
Silverstein, M. J., Lagios, M. D., Groshen, S., Waisman, J. R., Lewinsky, B. S., Martino, S., Gamagami, P., & Colburn, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401902 · Cited by 673
Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2010) · JNCI Monographs · doi:10.1093/jncimonographs/lgq039 · Cited by 672
Incidence of and Treatment for Ductal Carcinoma In Situ of the Breast
Ernster, V. L. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530360023033 · Cited by 626
Iqbal, J., Ginsburg, O., Rochon, P. A., Sun, P., & Narod, S. A. (2015) · JAMA · doi:10.1001/jama.2014.17322 · Cited by 614
Self-citationDetection of Ductal Carcinoma In Situ in Women Undergoing Screening Mammography
Ernster, V. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1546 · Cited by 582
Solin, L. J., Gray, R., Baehner, F. L., Butler, S. M., Hughes, L. L., Yoshizawa, C., Cherbavaz, D. B., Shak, S., Page, D. L., Sledge, G. W., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt067 · Cited by 518
Bijker, N., Peterse, J. L., Duchateau, L., Julien, J.-P., Fentiman, I. S., Duval, C., Di Palma, S., Simony-Lafontaine, J., de Mascarel, I., & van de Vijver, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2263 · Cited by 496
McCormick, B., Winter, K., Hudis, C., Kuerer, H. M., Rakovitch, E., Smith, B. L., Sneige, N., Moughan, J., Shah, A., Germain, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9029 · Cited by 392
Ernster, V. L., Barclay, J., Kerlikowske, K., Wilkie, H., & Ballard-Barbash, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.7.953 · Cited by 298
Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients
Schairer, C., Mink, P. J., Carroll, L., & Devesa, S. S. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh253 · Cited by 275
Recent Trends in Breast Cancer Among Younger Women in the United States
Brinton, L. A., Sherman, M. E., Carreon, J. D., & Anderson, W. F. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn344 · Cited by 267
Narod, S. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.102 · Cited by 254
Self-citationWärnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., Ringberg, A., Karlsson, P., Arnesson, L.-G., Anderson, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2595 · Cited by 228
Copson, E., Eccles, B., Maishman, T., Gerty, S., Stanton, L., Cutress, R. I., Altman, D. G., Durcan, L., Simmonds, P., Lawrence, G., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt134 · Cited by 213
Rosenberg, J., Chia, Y. L., & Plevritis, S. K. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1470-1 · Cited by 152
Impact of Ductal Carcinoma In Situ Terminology on Patient Treatment Preferences
Omer, Z. B., Hwang, E. S., Esserman, L. J., Howe, R., & Ozanne, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.8405 · Cited by 74
Punglia, R. S., Schnitt, S. J., & Weeks, J. C. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt256 · Cited by 42
Roland, C. L., & Hunt, K. (2015) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2015.04.007 · Cited by 30
Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?
Rakovitch, E., Mihai, A., Pignol, J., Hanna, W. M., Kwinter, J., Chartier, C., Ackerman, I., Kim, J., Pritchard, K. I., & Paszat, L. F. (2004) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-9454-8 · Cited by 28
Cited by
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
“The 20-year breast cancer mortality rate after treatment of DCIS is as low as 3% (24); whether this is due to the effectiveness of the interventions or the fact that most DCIS cases being treated are essentially benign is a pressing research question.”
BackgroundScreening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00008 · Cited by 1,686
Oeffinger, K. C., Fontham, E. T. H., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y.-C. T., Walter, L. C., Church, T. R., Flowers, C. R., LaMonte, S. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.12783 · Cited by 1,653
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0030 · Cited by 951
Metadata
- Authors
- Narod, S. A., Iqbal, J., Giannakeas, V., Sopik, V., & Sun, P.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-10-01
- Volume
- 1
- Issue
- 7
- Pages
- 888
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2127644335
- Cited by
- 613
- References
- 23
- FWCI
- 49.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.